uploads/2017/08/Part-1-Earnings-2Q17-1.png

Chemours Stock Fell despite Strong Earnings in 2Q17

By

Updated

Chemours’ 2Q17 earnings

Chemours (CC) reported its 2Q17 earnings on August 2, 2017, after the markets closed. The company’s management held a conference call on August 3, 2017, to discuss the earnings results. Chemours reported an adjusted EPS (earnings per share) of $0.87—an increase of 222.20% on a YoY (year-over-year) basis. In 2Q16, the company reported an adjusted EPS of $0.27. It also beat analysts’ estimate of $0.85 per share.

The increase in Chemours’ adjusted EPS was driven by higher volumes across its reporting segments. Its COGS (cost of goods sold) and SG&A (selling, general and administrative) expenses as a percentage of sales fell. Chemours reported COGS of $1.15 billion, which represented 72.20% of the sales. In 2Q16, Chemours’ COGS was $1.12 billion, which represented 80.70% of the sales. It fell by 850 basis points on a YoY basis.

Similarly, Chemours’ SG&A expenses for 3Q17 were $157 million, which represented 9.90% of the sales. In 3Q16, its SG&A expenses were $174 million, which represented 12.60% of the sales. It fell by 270 basis points on a YoY basis.

Stock price and guidance

Since its earnings were announced after the market hours on August 2, 2017, Chemours stock fell 1.70% the next day. On the same day, its peers Kronos Worldwide (KRO) and Tronox (TROX) fell 2% and 0.36%, respectively.

Now, Chemours expects to post adjusted EBITDA (earnings before, interest, tax, depreciation, and amortization) to be $1.3 billion–$1.4 billion in fiscal 2017—compared to its earlier guidance of $1.15 billion–$1.25 billion.

Investors can indirectly hold Chemours by investing in the PowerShares DWA Basic Materials Momentum Portfolio (PYZ). PYZ has invested 4.90% of its holding in Chemours. The fund also provides exposure to FMC (FMC) with a weight of 4.30% as of August 3, 2017.

In this series, we’ll discuss Chemours’ earnings, revenue, and analysts’ latest recommendations after 2Q17.

More From Market Realist